Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Is it time to consider rationalizing IFN-beta treatment in individuals with multiple sclerosis?

× No keyword cloud information.

5 in total

1. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies.

Authors: F Deisenhammer; M Reindl; J Harvey; T Gasse; E Dilitz; T Berger
Journal: Neurology Date: 1999-04-12 Impact factor: 9.910

2. Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys.

Authors: Donald E Mager; Berend Neuteboom; Constantinos Efthymiopoulos; Alain Munafo; William J Jusko
Journal: J Pharmacol Exp Ther Date: 2003-03-26 Impact factor: 4.030

3. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Authors: A Bertolotto; A Sala; S Malucchi; F Marnetto; M Caldano; A Di Sapio; M Capobianco; F Gilli
Journal: J Neurol Neurosurg Psychiatry Date: 2004-09 Impact factor: 10.154

4. Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years.

Authors: Francesca Bellomi; Carolina Scagnolari; Valentina Tomassini; Claudio Gasperini; Andrea Paolillo; Carlo Pozzilli; Guido Antonelli
Journal: J Neurol Sci Date: 2003-11-15 Impact factor: 3.181

5. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.

Authors: Andrew Pachner; Kavitha Narayan; Nicholson Price; Marie Hurd; Donna Dail
Journal: Mol Diagn Date: 2003

5 in total